121 related articles for article (PubMed ID: 9865424)
41. Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County.
London SJ; Daly AK; Leathart JB; Navidi WC; Carpenter CC; Idle JR
Carcinogenesis; 1997 Jun; 18(6):1203-14. PubMed ID: 9214604
[TBL] [Abstract][Full Text] [Related]
42. Genetic variants of the drug-metabolizing enzyme CYP2D6 in Puerto Rican psychiatry patients: a preliminary report and potential implications for breast cancer patients.
González-Tejera G; Gaedigk A; Corey S
P R Health Sci J; 2010 Sep; 29(3):299-304. PubMed ID: 20799519
[TBL] [Abstract][Full Text] [Related]
43. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease.
Kurth MC; Kurth JH
Am J Med Genet; 1993 Oct; 48(3):166-8. PubMed ID: 8291573
[TBL] [Abstract][Full Text] [Related]
44. Study design and genetic susceptibility factors in the risk assessment of chemical carcinogens.
Caporaso N
Ann Ist Super Sanita; 1991; 27(4):621-30. PubMed ID: 1820735
[TBL] [Abstract][Full Text] [Related]
45. Frequency of the variant allele CYP2D6(C) among North American Caucasian lung cancer patients and controls.
Shaw GL; Weiffenbach B; Falk RT; Frame JN; Issaq HJ; Moir DT; Caporaso N
Lung Cancer; 1997 May; 17(1):61-8. PubMed ID: 9194027
[TBL] [Abstract][Full Text] [Related]
46. Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphisms and schizophrenia.
Jönsson EG; Dahl ML; Roh HK; Jerling M; Sedvall GC
Psychiatr Genet; 1998; 8(1):25-8. PubMed ID: 9564684
[TBL] [Abstract][Full Text] [Related]
47. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.
Christensen PM; Gøtzsche PC; Brøsen K
Eur J Clin Pharmacol; 1997; 51(5):389-93. PubMed ID: 9049580
[TBL] [Abstract][Full Text] [Related]
48. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.
Saxena R; Shaw GL; Relling MV; Frame JN; Moir DT; Evans WE; Caporaso N; Weiffenbach B
Hum Mol Genet; 1994 Jun; 3(6):923-6. PubMed ID: 7951238
[TBL] [Abstract][Full Text] [Related]
49. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.
Johansson I; Oscarson M; Yue QY; Bertilsson L; Sjöqvist F; Ingelman-Sundberg M
Mol Pharmacol; 1994 Sep; 46(3):452-9. PubMed ID: 7935325
[TBL] [Abstract][Full Text] [Related]
50. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity.
Masimirembwa C; Persson I; Bertilsson L; Hasler J; Ingelman-Sundberg M
Br J Clin Pharmacol; 1996 Dec; 42(6):713-9. PubMed ID: 8971426
[TBL] [Abstract][Full Text] [Related]
51. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population.
Garcia-Barceló M; Chow LY; Chiu HF; Wing YK; Lee DT; Lam KL; Waye MM
Clin Chem; 2000 Jan; 46(1):18-23. PubMed ID: 10620567
[TBL] [Abstract][Full Text] [Related]
52. Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype.
Wennerholm A; Johansson I; Massele AY; Lande M; Alm C; Aden-Abdi Y; Dahl ML; Ingelman-Sundberg M; Bertilsson L; Gustafsson LL
Pharmacogenetics; 1999 Dec; 9(6):707-14. PubMed ID: 10634133
[TBL] [Abstract][Full Text] [Related]
53. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.
Kagimoto M; Heim M; Kagimoto K; Zeugin T; Meyer UA
J Biol Chem; 1990 Oct; 265(28):17209-14. PubMed ID: 2211621
[TBL] [Abstract][Full Text] [Related]
54. CYP2D6 polymorphism in patients with eating disorders.
Peñas-Lledó EM; Dorado P; Agüera Z; Gratacós M; Estivill X; Fernández-Aranda F; Llerena A
Pharmacogenomics J; 2012 Apr; 12(2):173-5. PubMed ID: 20877302
[TBL] [Abstract][Full Text] [Related]
55. [G138A polymorphism of the RNASEL gene and its association with the development of prostate cancer. Preliminary study].
Zabala W; Delgado C; Pardo T; Borjas L; Rojas-Atencio A; Reyes F; Quintero JM
Invest Clin; 2009 Sep; 50(3):295-301. PubMed ID: 19961052
[TBL] [Abstract][Full Text] [Related]
56. CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers.
Llerena A; Dorado P; Ramírez R; Calzadilla LR; Peñas-Lledó E; Álvarez M; Naranjo ME; González I; Pérez B;
Pharmacogenomics; 2013 Dec; 14(16):1973-7. PubMed ID: 24279852
[TBL] [Abstract][Full Text] [Related]
57. Rapid and comprehensive determination of cytochrome P450 CYP2D6 poor metabolizer genotypes by multiplex polymerase chain reaction.
Roberts R; Joyce P; Kennedy MA
Hum Mutat; 2000; 16(1):77-85. PubMed ID: 10874309
[TBL] [Abstract][Full Text] [Related]
58. Genetic polymorphism and Parkinson's disease in Taiwan: study of debrisoquine 4-hydroxylase (CYP2D6).
Lo HS; Chen CH; Hogan EL; Kao KP; Wang V; Yan SH
J Neurol Sci; 1998 Jun; 158(1):38-42. PubMed ID: 9667775
[TBL] [Abstract][Full Text] [Related]
59. The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype.
Caporaso NE; Shields PG; Landi MT; Shaw GL; Tucker MA; Hoover R; Sugimura H; Weston A; Harris CC
Environ Health Perspect; 1992 Nov; 98():101-5. PubMed ID: 1362537
[TBL] [Abstract][Full Text] [Related]
60. CYP2D6 polymorphism in systemic lupus erythematosus patients.
Kortunay S; Bozkurt A; Bathum L; Basci NE; Calgüneri M; Brøsen K; Kayaalp SO
Eur J Clin Pharmacol; 1999 Mar; 55(1):21-5. PubMed ID: 10206080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
